Psychotogenic N,N-Dimethylated Indole Amines and Behavior in Schizophrenic Patients

  • H. Tanimukai
  • R. Ginther
  • J. Spaide
  • J. R. Bueno
  • H. E. Himwich


The presence of norepinephrine, dopamine, and serotonin in the brain of mammals (including man) has been confirmed repeatedly, and the possible physiological role of these amines in the cerebral functions has been discussed. Many neuropsychotropic drugs used in the treatment of mental patients are known to affect the cerebral level of these primary amines. In contrast, N,N-dimethylated indole amines (in the right column in Fig. 1) have evoked psychotomimetic effects in human beings [1–4] or caused behavioral disturbances in experimental animals [5], Axelrod [6, 7] has demonstrated by in vitro studies that such N,N-dimethylated indole amines could be formed in mammalian tissues from the naturally occurring primary indole amines, such as tryptamine or serotonin. In this reaction, the tryptamine moiety of such N,N-dimeth-ylated indole amines is originally derived from the essential amino acid, tryptophan (Fig. 1), and the methyl groups can be supplied by a methyl donor such as methionine or betaine.


Psychotic Symptom Schizophrenic Patient Indole Amine Trimethylsilyl Ether Mental Symptom 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fabing, H.D., and Hawkins, J.R.: Intravenous bufotenin injection in the human being, Science 123:886, 1956.PubMedCrossRefGoogle Scholar
  2. 2.
    Szara, S.: Dimethyltryptamine: Its metabolism in man: The relation of its psychotic effect to the serotonin metabolism, Experientia 12:441, 1956.PubMedCrossRefGoogle Scholar
  3. 3.
    Arnold, D. H., and Hofmann, G.: Zur Psychopathologie des Dimethyltryptamin: ein weiterer Beitrag zur Pharmakopsychiatrie: vorläufige Mitteilung, Wien. Z. Nervenheilk. 13:438, 1957.PubMedGoogle Scholar
  4. 4.
    Rosenberg, D.E., Isbell, H., and Miner, E. J.: Comparison of a placebo, N-dimethyltrypta-mine, and 6-hydroxy-N-dimethyltryptamine in man, Psychopharmacologia 4:39, 1963.PubMedCrossRefGoogle Scholar
  5. 5.
    Gessner, P.K., and Page, I.H.: Behavioral effects of 5-methoxy-N,N-dimethyltryptamine, other tryptamines, and LSD, Am. J. Physiol. 203:167, 1962.Google Scholar
  6. 6.
    Axelrod, J.: Enzymatic formation of psychotomimetic metabolites from naturally occurring compounds, Science 134:343, 1961.PubMedCrossRefGoogle Scholar
  7. 7.
    Axelrod, J.: The enzymatic N-methylation of serotonin and other amines, J. Pharmacol. Exptl. Therap. 138:28, 1962.Google Scholar
  8. 8.
    Pollin, W., Cardon, P.V., and Kety, S.S.: Effects of amino acid feeding in schizophrenic patients treated with iproniazid, Science 133:104, 1961.PubMedCrossRefGoogle Scholar
  9. 9.
    Brune, G.G., and Himwich, H.E.: Effects of methionine loading on the behavior of schizophrenic patients, J. Nerv. Ment. Dis. 134:447, 1962.PubMedCrossRefGoogle Scholar
  10. 10.
    Alexander, F., Curtis, G.C., Sprince, H., and Crosley, A.P.: L-Methionine and L-tryptophan feedings in non-psychotic and schizophrenic patients with and without tranylcypromine, J. Nerv. Ment. Dis. 137:135, 1963.PubMedCrossRefGoogle Scholar
  11. 11.
    Haydu, G.G., Dhrymiotis, A., Korenyi, C, and Goldschmidt, L.: Effect of methionine and hydroxychloroquine in schizophrenia. Am. J. Psychiat. 122:560, 1965.PubMedGoogle Scholar
  12. 12.
    Park, L.C., Baldessarini, R. J., andKety, S.S.: Methionine effects on chronic schizophrenics, Arch. Gen. Psychiat. 12:346, 1965.PubMedCrossRefGoogle Scholar
  13. 13.
    Beriet, H.H., Matsumoto, K., Pscheidt, G.R., Spaide, J., Bull, C., and Himwich, H.E.: Biochemical correlates of behavior in schizophrenic patients, Arch. Gen. Psychiat. 13:521, 1965.CrossRefGoogle Scholar
  14. 14.
    Brune, G. G.: Metabolism of biogenic amines and psychotropic drug effects in schizophrenic patients, in: Himwich, W.A., and Schade, J.P. (eds.), Progress in Brain Research, Horizons in Neuropsychopharmacology, Vol. 16, Elsevier, Amsterdam, 1963, p. 81.Google Scholar
  15. 15.
    Fischer, E., Lagravere, T.A.F., Vazquez, A. J., and Distefano, A.O.: A bufotenin-like substance in the urine of schizophrenics, J. Nerv. Ment. Dis. 133:441, 1961.PubMedCrossRefGoogle Scholar
  16. 16.
    Brune, G.G., Kohl, H.H., and Himwich, H.E.: Urinary excretion of bufotenin-like substance in psychotic patients, J. Neuropsychiat. 5:14, 1963.Google Scholar
  17. 17.
    Heller, B.: Influence of treatment with an amino oxidase inhibitor on the excretion of bufotenin and the clinical symptoms in chronic schizophrenic patients. Int. J. Neuropsychiat. 2:193, 1966.Google Scholar
  18. 18.
    Bumpus, F.M., and Page, I. H.: Serotonin and its methylated derivatives in human urine, J. Biol. Chem. 212:111, 1955.PubMedGoogle Scholar
  19. 19.
    Perry, T.L., Shaw, K.N.F., Walker, D., and Redlich, D.: Urinary excretion of amines in normal children, Pediatrics 30:576, 1962.Google Scholar
  20. 20.
    Gross, H., and Franzen, F.: Zur Bestimmung körpereigener Amine in biologischen Substraten. I. Beitrag zur Bestimmung von Bufotenin in menschlichem Blut und Harn, Biochem. Z. 340:403, 1964.PubMedGoogle Scholar
  21. 21.
    Tanimukai, H.: Modifications of paper and thin layer chromatographic methods to increase sensitivity for detecting N-methylated indoleamines in urine, J. Chromatog. 30:155, 1967.CrossRefGoogle Scholar
  22. 22.
    Siegel, M.: A sensitive method for detection of N,N-dimethylserotonin (bufotenin) in urine: Failure to demonstrate its presence in the urine of schizophrenic and normal subjects, J. Psychiat. Res. 3:205, 1965.PubMedCrossRefGoogle Scholar
  23. 23.
    Rodnight, R.: Separation and characterization of urinary indoles resembling 5-hydroxy-tryptamine and tryptamine, Biochem. J. 64:621, 1956.PubMedGoogle Scholar
  24. 24.
    Feldstein, A., Hoagland, H., and Freeman, H.: Radioactive serotonin in relation to schizophrenia, Arch. Gen. Psychiat. 5:246, 1961.PubMedCrossRefGoogle Scholar
  25. 25.
    Sprince, H., Parker, CM., Jameson, D., and Alexander, F.: Urinary indoles in schizophrenic and psychoneurotic patients after administration of tranylcypromine (Parnate) and methionine or tryptophan, J. Nerv. Ment. Dis. 137:246, 1963.PubMedCrossRefGoogle Scholar
  26. 26.
    Takesada, M., Miyamoto, E., Kakimoto, Y., Sano, I., and Kaneko, Z.: Phenolic and indole amines in the urine of schizophrenics, Nature 207:1199, 1965.PubMedCrossRefGoogle Scholar
  27. 27.
    Runge, T.M., Lara, F.Y., Thurman, N., Keyes, J.W., and Hoerster, S. H.: Search for a bufotenin-like substance in the urine of schizophrenics, J. Nerv. Ment. Dis. 142:470, 1966.PubMedCrossRefGoogle Scholar
  28. 28.
    Perry, T.L., Hansen, S., MacDougall, L., and Schwarz, C.J.: Urinary amines in chronic schizophrenia, Nature 212:146, 1966.PubMedCrossRefGoogle Scholar
  29. 29.
    Spaide, J., Tanimukai, H., Ginther, R., Bueno, J.R., and Himwich, H.E.: Schizophrenic behavior and urinary tryptophan metabolites associated with cysteine given with and without a monoamine oxidase inhibitor (tranylcypromine). Life Sciences 6:507, 1967.CrossRefGoogle Scholar
  30. 30.
    Tanimukai, H., Ginther, R., Spaide, J., Bueno, J.R., and Himwich, H.E.: Detection of psychotomimetic N,N-dimethylated indoleamines in the urine of schizophrenic patients, J. Psychiat. Res. (in press).Google Scholar
  31. 31.
    Capella, P., and Horning, E.C.: Separation and identification of derivatives of biologic amines by gas-liquid chromatography, Anal. Chem. 38:316, 1966.PubMedCrossRefGoogle Scholar
  32. 32.
    Downing, D.F.: Psychotomimetic compounds, in: Gordon, M. (ed.), Psychopharmacological Agents, Vol. 1, Academic Press, New York, 1964, pp. 555–618.Google Scholar

Copyright information

© Springer Science+Business Media New York 1968

Authors and Affiliations

  • H. Tanimukai
  • R. Ginther
  • J. Spaide
  • J. R. Bueno
  • H. E. Himwich

There are no affiliations available

Personalised recommendations